首页 > 市场调查报告书 > 製药

荷尔蒙避孕药市场规模、份额和成长分析（按产品、荷尔蒙、年龄、最终用户和地区划分）：产业预测（2026-2033 年）

市场调查报告书

商品编码

1896865

荷尔蒙避孕药市场规模、份额和成长分析（按产品、荷尔蒙、年龄、最终用户和地区划分）：产业预测（2026-2033 年）

Hormonal Contraceptive Market Size, Share, and Growth Analysis, By Product, By Hormones, By Age, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，全球荷尔蒙避孕药市场规模将达到 201.1 亿美元，到 2025 年将达到 209.5 亿美元，到 2033 年将达到 291.2 亿美元，预测期（2026-2033 年）的复合年增长率为 4.2%。

全球荷尔蒙避孕药市场正经历显着扩张，这主要得益于人们对避孕方法的认知和接受度不断提高，以及对有效计划生育方案需求的日益增长。虽然这些方法能有效预防怀孕，但并不能性行为感染感染（STI），因此仍需采取其他预防措施。消费者越来越倾向选择口服避孕药，尤其是复方口服避孕药。由于其高效性和易用性，复方口服避孕药占据了市场主导地位。然而，仅含黄体素的避孕药也已成为一个重要的细分市场，并有望加速成长，因为其副作用极小，且适用于无法耐受雌激素的女性。这种动态的市场格局反映了偏好的转变以及对可靠生殖健康方案的持续追求。

全球荷尔蒙避孕药市场驱动因素

全球荷尔蒙避孕药市场的成长主要得益于人们对避孕作为重要计划生育手段的认识和接受度不断提高。随着人口持续增长，尤其是在发展中地区，人们对有效避孕方法的需求日益迫切，以帮助夫妻有效控製家庭规模和生育间隔。这种日益增长的需求导致荷尔蒙避孕药的使用量显着增加，研究表明，荷尔蒙避孕药在预防意外怀孕方面非常有效。此外，荷尔蒙避孕药的便利性和可逆性使其成为寻求可靠计划生育方法人士的理想选择。

全球荷尔蒙避孕药市场受到压制

全球荷尔蒙避孕药市场面临严峻挑战，社会和文化因素阻碍了女性获得避孕服务。在不同的文化和社会中，避孕往往被视为负面行为，某些宗教信仰甚至强烈反对使用避孕措施。此外，许多地区对避孕方法的认知和教育不足也导致需求低落。这些问题严重限制了市场成长，尤其是在文化规范和社会态度对避孕决策有显着影响的地区。因此，克服这些障碍对于提高全球荷尔蒙避孕药的可及性和接受度至关重要。

全球荷尔蒙避孕药市场趋势

全球荷尔蒙避孕市场正经历着长效可逆避孕方法（LARCs）的显着转变，例如子宫内避孕器（IUD）和植入式。这反映出消费者对高效率、长效避孕方案的需求日益增长。 LARCs具有显着优势——高效且长期维护成本低——使其成为追求可靠性和便利性的女性的理想选择。这趋势在年轻女性中尤其明显，除了重视避孕效果外，她们也十分重视产品的易用性。因此，生产商正致力于拓展LARCs产品线，改善产品获取途径，并加大教育投入，以提高大众对这些避孕方法的认知度并推广其使用。

拜耳股份公司（德国）
辉瑞公司（美国）
默克公司（美国）
强生公司（美国）
艾伯维公司（美国）
梯瓦製药工业股份有限公司（以色列）
迈兰公司（美国）
Viatris公司（美国）
Organon & Co.（美国）
Mithra製药（比利时）
Agile Therapeutics, Inc.（美国）
Mayne Pharma Group Limited（澳洲）
Afaxys公司（美国）
Pregna 国际有限公司（印度）
鲁宾製药公司（印度）
西普拉有限公司（印度）
太阳製药工业有限公司（印度）
Piramal Enterprises Limited（印度）

结论与建议

简介目录

Product Code: SQMIG35I2132

Global Hormonal Contraceptive Market size was valued at USD 20.11 Billion in 2024 and is poised to grow from USD 20.95 Billion in 2025 to USD 29.12 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

The global market for hormonal contraceptives is experiencing significant expansion, driven by heightened awareness and acceptance of contraceptive options along with a rising demand for effective family planning solutions. While these methods excel at preventing pregnancy, they do not offer protection against sexually transmitted infections (STIs), necessitating additional protective measures. Consumers are increasingly opting for oral contraceptives, particularly combination pills, which dominate the market due to their efficacy and ease of use. However, progestin-only pills are emerging as a strong segment, anticipated to witness accelerated growth owing to their minimal side effects and compatibility for women unable to use oestrogen. This dynamic landscape reflects shifting preferences and the ongoing pursuit of reliable reproductive health options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptive Market Segments Analysis

Global Hormonal Contraceptive Market is segmented by Product, Hormones, End User, Age and region. Based on Product, the market is segmented into Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches. Based on Hormones, the market is segmented into Progestin Only Contraceptive and Combined Hormonal Contraceptive. Based on Age, the market is segmented into 15-24 Years, 25-34 Years, 35-44 Years and Above 44 Years. Based on End User, the market is segmented into Hospitals, Household and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is significantly driven by the heightened awareness and acceptance of contraception as a vital tool for family planning. As population growth continues, especially in developing regions, the demand for effective birth control solutions becomes increasingly pressing to help couples effectively manage family size and spacing. This burgeoning need has resulted in a notable rise in the utilization of hormonal contraceptives, which are recognized for their high efficacy in preventing unintended pregnancies. Additionally, their convenience and reversibility make hormonal contraceptives an attractive option for those seeking reliable family planning methods.

Restraints in the Global Hormonal Contraceptive Market

The global hormonal contraceptive market faces notable challenges stemming from social and cultural factors that hinder women's access to contraceptives. In various cultures and societies, contraception is often perceived unfavorably, with certain religious beliefs actively opposing its use. Additionally, limited awareness and education regarding contraceptive options further contribute to decreased demand in numerous regions. These issues significantly restrict market growth, particularly in areas where cultural norms and societal attitudes heavily influence decisions about contraceptive use. As a result, overcoming these barriers is crucial for enhancing accessibility and acceptance of hormonal contraceptives worldwide.

Market Trends of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is witnessing a notable shift towards long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) and subdermal implants, reflecting a growing consumer preference for effective, long-term birth control solutions. LARCs offer significant advantages, including high efficacy rates and minimal maintenance over extended periods, making them appealing to women seeking reliable and convenient contraceptive options. This trend is particularly prevalent among younger demographics, who are prioritizing not only effectiveness but also ease of use. Consequently, manufacturers are focusing on expanding LARC offerings, enhancing accessibility, and investing in educational initiatives to promote awareness and utilization of these options.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Hormonal Contraceptive Market Size by Product & CAGR (2026-2033)

Market Overview
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Rings
Transdermal Patches

Global Hormonal Contraceptive Market Size by Hormones & CAGR (2026-2033)

Market Overview
Progestin Only Contraceptive
Combined Hormonal Contraceptive

Global Hormonal Contraceptive Market Size by Age & CAGR (2026-2033)

Market Overview
15-24 Years
25-34 Years
35-44 Years
Above 44 Years

Global Hormonal Contraceptive Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Household
Clinics

Global Hormonal Contraceptive Market Size & CAGR (2026-2033)

North America (Product, Hormones, End User, Age)
- US
- Canada
Europe (Product, Hormones, End User, Age)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Hormones, End User, Age)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Hormones, End User, Age)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Hormones, End User, Age)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organon & Co. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mithra Pharmaceuticals (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agile Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mayne Pharma Group Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Afaxys, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pregna International Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments